Potential role of various dosimetric quality indicators in prostate brachytherapy

被引:56
作者
Merrick, GS
Butler, WM
Dorsey, AT
Lief, JH
机构
[1] Wheeling Hosp, Schiffler Oncol Ctr, Wheeling, WV 26003 USA
[2] George Washington Univ, Med Ctr, Div Radiat Oncol & Biophys, Washington, DC 20037 USA
[3] Wheeling Jesuit Univ, Wheeling, WV USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1999年 / 44卷 / 03期
关键词
prostate brachytherapy; quality indicators; dosimetry;
D O I
10.1016/S0360-3016(99)00067-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Postoperative CT-based dosimetric analysis provides detailed information regarding the coverage and uniformity of an implant, but the assessment of implant quality remains an unanswered and controversial issue. There is no disagreement that a good implant should cover the target volume with an adequate dose, but there is no consensus as to what represents an adequate dose. Materials and Methods: The American Brachytherapy Society has recently proposed that prostate brachytherapy quality be measured in terms of the following parameters: D90, V100, and V150 where D90 is defined as the minimal dose covering 90% of the prostate volume and V100 and V150 are defined as the percent volume of the prostate receiving at least 100% or 150% of the prescribed minimal peripheral dose (mPD), respectively. We report detailed day 0 dosimetric evaluation for 60 consecutive prostate brachytherapy patients implanted via a standard transperineal ultrasound guided approach in terms of D90, D100, V90, V100, and V150 and also the maximal and average rectal and urethral dose. Results: Dosimetric evaluation resulted in a V100 greater than 80% of the prostate volume and a D90 greater than 90% of the mPD in the entire patient population. There was a statistically significant difference between the quality scores of I-125 implants and Pd-103 implants with the I-125 mean V100 and D90 at 95.3% volume and 109.9% mPD, respectively, vs. Pd-103 at 91.8% volume and 103.7% mPD. Likewise, the rectal and urethral doses as a fraction of mPD were significantly lower in Pd-103 than in I-125 implants. This occurred despite the fact that palladium implants were typically preplanned with significantly better coverage and hotter V150 than iodine implants. We consider V150 to be an important parameter for determining dose homogeneity although the clinical utility of dose homogeneity remains unknown. The mean V150 was 45.6 +/- 9.6% volume. There was no additional dosimetric utility from a determination of V90 while D100 was found to be overly sensitive to steep dose gradients at the periphery of the prostate. Conclusions: This report represents the first detailed postimplant day 0 dosimetric evaluation comparing ABS recommended quality parameters used to evaluate prostate brachytherapy. At the present time, no long-term clinical outcomes are available because of short follow-up. As PSA based follow-up data becomes available, however, this report may help define what represents an adequate implant. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:717 / 724
页数:8
相关论文
共 40 条
[1]  
BICE WS, 1997, J BRACHYTHER INT, V13, P297
[2]  
Blasko, 1993, Semin Radiat Oncol, V3, P240, DOI 10.1016/S1053-4296(05)80121-3
[3]   PROSTATE-SPECIFIC ANTIGEN BASED DISEASE-CONTROL FOLLOWING ULTRASOUND-GUIDED (125)IODINE IMPLANTATION FOR STAGE T1/T2 PROSTATIC-CARCINOMA [J].
BLASKO, JC ;
WALLNER, K ;
GRIMM, PD ;
RAGDE, H .
JOURNAL OF UROLOGY, 1995, 154 (03) :1096-1099
[4]  
Blasko John, 1996, International Journal of Radiation Oncology Biology Physics, V36, P198, DOI 10.1016/S0360-3016(97)85421-1
[5]   Quality assurance calibration of 125I Rapid Strand in a sterile environment [J].
Butler, WM ;
Dorsey, AT ;
Nelson, KR ;
Merrick, GS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (01) :217-222
[6]  
BUTLER WM, UNPUB ISOTOPE CHOICE
[7]   Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer [J].
Critz, FA ;
Levinson, K ;
Williams, WH ;
Holladay, D ;
Holladay, C ;
Griffin, V .
UROLOGY, 1997, 49 (05) :668-672
[8]   Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer [J].
Critz, FA ;
Levinson, AK ;
Williams, WH ;
Holladay, DA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) :2893-2900
[9]   Pd-103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma [J].
Dattoli, M ;
Wallner, K ;
Sorace, R ;
Koval, J ;
Cash, J ;
Acosta, R ;
Brown, C ;
Etheridge, J ;
Binder, M ;
Brunelle, R ;
Kirwan, N ;
Sanchez, S ;
Stein, D ;
Wasserman, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (05) :875-879
[10]  
Dattoli MJ, 1997, INT J RADIAT ONCOL, V39, P221